Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 79,410 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: ARX788; Drug
Lead sponsor: Ambrx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more

Conditions: Atopic Dermatitis, Type 1 Hypersensitivity
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 0 Days to 14 Days
Enrollment: 283 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Parkinson Disease
Interventions: Motivational Interviewing, Web-based application; Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant, Granisetron, dexamethasone, Placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Radiation Exposure
Interventions: Prone hyperpolarized 3 helium gas scan, Supine hyperpolarized 3 helium gas scan, Vitals, Pulmonary Function Tests, Initial protocol MRI scan; Drug · Diagnostic Test
Lead sponsor: Eric A. Hoffman; Other
Eligibility: 18 Years to 90 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Lung Diseases
Interventions: eCO testing; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Mental Health
Interventions: Immigrant Well-Being Project; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Acne Vulgaris
Interventions: Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care; Drug · Behavioral
Lead sponsor: Wake Forest University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pulmonary Sarcoidosis
Interventions: Pentoxifylline; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pre-hypertension, Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Nurown MSC-NTF cells, Placebo; Biological
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Avelumab, Berzosertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Malignant Neoplasm
Interventions: assessment of therapy complications, laboratory biomarker analysis; Procedure · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chickenpox
Interventions: Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 1,840 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more

Conditions: Breast Neoplasms
Interventions: Docetaxel, Doxorubicin, Carboplatin, Cyclophosphamide, Trastuzumab, Bevacizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Metastatic Melanoma
Interventions: MLN4924; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Atrial Fibrillation
Interventions: Study arm; Behavioral
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years to 85 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Stress, Stress Disorder, Stress, Psychological, Trauma, Psychological, Anxiety, Anxiety State, Post Traumatic Stress Disorder, Secondary Traumatic Stress, Professional Quality of Life, Stress Related Disorder, Stress Reaction, Stress Risk, Mental Resilience, Emotional Resilience
Interventions: MinnRAP Peer Support Program; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Minor Surgical Procedures With Monitored Anesthesia Care, Driving Performance After Minor Ambulatory Surgery
Interventions: Midazolam, Sufentanil, Propofol; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 21 Years to 70 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis
Interventions: Ruxolitinib, Tasquinimod; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Interventions: PF-08634404, Enfortumab Vedotin; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 164
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 100 more

Conditions: Influenza, Human
Interventions: F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD; Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 845 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 18
States / cities: Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more

Conditions: Cervical Cancer, Endometrial Cancer
Interventions: 18F-Fluorodeoxyglucose (18F-FDG), PET/CT imaging, PET/MRI imaging; Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Allergic Disease Onset Prevention Study

Motivational Interviewing and Physical Activity Change in Parkinson's Disease

Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy

Repeatability in Hyperpolarized 3-Helium With MRI

Exhaled Carbon Monoxide (eCO) for Diffusing Capacity (DLCO) Correction

Immigrant Well-being Project: Transdisciplinary Ecological Mental Health Intervention for Mexican Immigrants

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

Treatment of Pulmonary Sarcoidosis With Pentoxifylline

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

Characteristics of Glargine in Type 2 Diabetics

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Dose Escalation Study of MLN4924 in Adults With Melanoma

Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognition in AF

The Professional Peer Resilience Initiative

Safety of Driving After Minor Surgery With Monitored Anesthesia Care

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer